50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to transform the treatment of serious ophthalmic disease by fully exploiting the Wnt pathway.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2390% match
“Our mission is to develop disease-modifying, regenerative therapies to restore vision to millions of patients.”In use 2025 – now·1 sighting·SEC Form S-1, filed 2025-01-2472% match
“Our mission is to develop, manufacture and distribute worldwide visual implants and other ophthalmic products that improve the vision of patients with cataracts, refractive conditions and glaucoma.”In use 2005 – now·1 sighting·SEC Form 10-K/A, filed 2005-04-2170% match
“Our mission is to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0470% match
“Our mission is to develop and commercialize novel therapeutics to treat diseases of the eye, with an initial focus on diseases of the back of the eye.”In use 2005 – now·1 sighting·SEC Form 10-K, filed 2005-03-2169% match
“Our mission is to maintain and restore sight in patients by building the leading vertically integrated retinal gene therapy company.”In use 2017 – now·1 sighting·SEC Form 424B4, filed 2017-09-2869% match
“Our mission is to create transformative gene-based medicines for serious human diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-1268% match
“Our mission is to build the world’s leading endocrine company that pioneers new therapeutics to help patients better control their disease and improve their daily lives.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2668% match
“Our mission is to build a leading, fully integrated global rare disease company using our patient-centric approach to identify and develop life-transforming medicines for the treatment of severe rare diseases.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-04-1968% match
“Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2567% match
“Our mission is to translate the promise of gene editing into a broad class of differentiated, transformational medicines for previously untreatable diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0967% match
“Our mission is to develop innovative, transformative therapies for patients with devastating diseases through the use of our novel chRDNA genome-editing technology.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0567% match
“Our mission is to build a major ophthalmic pharmaceutical company.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-02-2767% match
“Our mission is to create, develop, manufacture, and deliver cell and gene therapies to transform the lives of people impacted by life-threatening diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1866% match
“Our mission is to expand our portfolio into a wide range of muscle diseases and become a leader in this area by advancing life-transforming therapeutics for patients with serious muscle diseases.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-0466% match
“Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2666% match
“Our mission is to transform the lives of patients living with devastating genetic diseases by building the leading integrated genetic medicine company focused on developing and commercializing potentially curative therapeutics based on our GeneRide platform.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-1566% match
“Our mission is to improve the vision health and quality of life of patients around the world by developing medicines that save sight and improve eye care for patients.”In use 2025 – now·1 sighting·SEC Form 20-F, filed 2025-03-1166% match
“Our mission is to translate complex, powerful biology with rigor and urgency into life-changing medicines.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1166% match
“Our mission is to significantly improve patient outcomes and address areas of high unmet medical need with our nanotechnology-based therapies.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-12-1166% match
“Our mission is to discover, develop and commercialize novel and transformative therapies that improve the lives of patients with serious diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2265% match
“Our mission is to become a global leader in the treatment of rare diseases through commercializing, developing and acquiring novel rare disease products.”In use 2021 – now·1 sighting·SEC Form 424B4, filed 2021-01-1465% match
“Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases.”In use 2026 – now·1 sighting·SEC Form 424B4, filed 2026-05-0165% match
“Our mission is to build an ophthalmology-focused biopharmaceutical company that capitalizes on the gaps that we believe increasingly exist in the ophthalmology sector between single product companies and large, multi-product pharmaceutical companies.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-0665% match
“Our mission is to transform the lives of patients through the creation of novel gene control medicines by building a fully integrated, leading biopharmaceutical company.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-03-2065% match
“Our mission is to discover, develop and ultimately deliver medicines that are transformational for patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2865% match
“Our mission is to deliver innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-2465% match
“Our mission is to develop transformative therapies that prevent and eliminate metabolic disease.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2465% match
“Our mission is to leverage our unique insights into the chromatin regulatory system to pioneer the discovery, development and commercialization of a new class of therapies that transform the lives of patients suffering from a wide spectrum of diseases with high unmet need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1165% match
“Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2665% match
“Our mission is to develop transformative medicines to improve the lives of patients with central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy and other diseases associated with dysregulation or overexpression of filamin A. Our science is based on modulating the activity of a critical protein in the brain for patients with certain CNS disorders, such as TSC.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1265% match
“Our mission is to develop next generation cell and gene therapeutics with the capacity to cure.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0765% match
“Our mission is to build a breakthrough oncology company creating neoantigen-based therapies that significantly improve the lives of patients.”In use 2018 – now·1 sighting·SEC Form 424B4, filed 2018-06-2865% match
“Our mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function to enable patients with these disorders to live fuller and healthier lives.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-04-2365% match
“Our mission is to enable patients with these disorders to live fuller and healthier lives through the discovery and development of transformative precision peptide therapies.”In use 2025 – now·1 sighting·SEC Form 424B4, filed 2025-09-2564% match
“Our mission is to develop and commercialize therapies with the potential to transform the lives of patients and their families living with rare diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-0164% match
“Our mission is to advance novel therapies, leveraging evidence-based innovation, with the potential to transform the lives of people suffering from serious, chronic conditions and unmet medical needs.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-09-2564% match
“Our mission is to revolutionize regenerative medicine by bioengineering patient-specific Cellspan implants that use the patient’s own mesenchymal stromal cells to stimulate organ regeneration and restore an organ’s structure and continuity.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-04-1364% match
“Our mission is to become the leading company in precision genetic medicines by discovering, developing, manufacturing, and ultimately commercializing a new class of medicines through our proprietary base editing technology, with the goal of providing life-long cures to patients suffering from serious diseases.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-10-0164% match
“Our mission is to create disease-modifying neurogenetic medicines by identifying validated targets, advancing multiple therapeutic modalities, and delivering them to the right areas within the central nervous system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1164% match
“Our mission is to bring new medicines to patients suffering from blinding diseases, and we think you can play a key role in helping make our vision a reality.”In use 2014 – now·1 sighting·SEC Form S-1, filed 2014-06-3064% match
“Our mission is to be the global leader and pioneer of this new treatment paradigm, integrating recombinant technology, gene therapy and cell therapy to address the challenges of targeting and delivering effective therapies, including to the brain for cancer and other central nervous system (“CNS”) indications.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2864% match
“Our mission is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2364% match
“Our mission is to develop treatments for serious diseases.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2264% match
“Our mission is to deliver transformative therapeutics to those in need, and we believe our innovative EDO technology is well-positioned to effect this change for patients, families and the broader healthcare community.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0464% match
“Our mission is to empower physicians globally to deliver the transformative benefits of regenerative medicine—stem cell therapies, exosomes, peptides, and advanced combination protocols—to patients seeking effective, natural alternatives to traditional surgical, palliative, or symptom-management approaches.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-05-1464% match
“Our mission is to advance to market novel regenerative medicine and cellular therapy products that substantially benefit humankind.”In use 2016 – now·1 sighting·SEC Form S-1/A, filed 2016-02-0264% match
“Our mission is to provide superior treatment options for complex diseases and disorders to improve the lives of patients by developing innovative new medicines that exploit the unique role of NNRs.”In use 2012 – now·1 sighting·SEC Form 10-K, filed 2012-03-0664% match
“Our mission is to discover, develop, and deliver novel, life-transforming therapies to people suffering from rare, severe, and devastating neuromuscular diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0364% match
“Our mission is to improve human health and quality of life by transforming the way therapeutics and materials are discovered.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2564% match
Showing 1–50 of 50